Clinical Trials Logo
  1. Home
  2. Thalassemia Major
  3. NCT04009525

Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major: A Multicenter, Prospective Clinical Study

Thalassemia Major Clinical Trial

Official title:
Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major: A Multicenter, Prospective Clinical Study

Clinical Trial Summary

The only curative therapy for thalassemia major remains the replacement of the defective erythropoiesis by allogeneic hematopoietic stem cell transplantation(allo-HSCT). We conduct a prospective multicenter study to evaluate the efficacy of allo-HSCT in the treatment of thalassemia major.

Clinical Trial Description

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is one of the established curative option for thalassemia major (TM). Previous study has predicted that more than 90% of TM patients can survive after allo-HSCT with a thalassemia-free survival (TFS) in around 80% of them.The purpose of this study is to evaluate the efficacy of allo-HSCT in the treatment of thalassemia major. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04009525
Study type Interventional
Source First Affiliated Hospital of Guangxi Medical University
Contact Yongrong Lai, MD
Phone +86(0771)5356510
Email laiyongrong@hotmail.com
Status Recruiting
Phase Phase 4
Start date June 1, 2019
Completion date May 31, 2023
View Details
See also
  Status Clinical Trial Phase
Completed NCT02559648 - Denosumab vs Placebo in Patients With Thalassemia Major and Osteoporosis Phase 2
Recruiting NCT02126046 - Unrelated Umbilical Cord Blood Following HLA-haploidentical Hematopoietic Stem Cell Transplantation in Patients With β-thalassemia Major N/A
Completed NCT01125254 - Amlodipine Use in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major Phase 2/Phase 3
Terminated NCT00034528 - Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia Phase 2
Completed NCT00733811 - Efficacy Study of the Use of Sequential DFP-DFO Versus DFP Phase 4
Enrolling by invitation NCT02986698 - In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM) Phase 1
Not yet recruiting NCT06026839 - Longitudinal Study on the QoL of Pediatric Patients After HSCT and Its Influencing Factors
Terminated NCT00007072 - Phase II Study of Azacitidine and Phenylbutyrate in Patients With Thalassemia Major Phase 2
Completed NCT04292314 - Hydroxy Urea, Omega 3, Nigella Sativa,Honey on Oxidative Stress and Iron Chelation in Pediatric Major Thalassemia Phase 2/Phase 3
Completed NCT02049450 - Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia. Phase 2
Active, not recruiting NCT04523376 - Pilot Study PBSCT With TCRab Depletion For Hemoglobinopathies N/A
Completed NCT03992001 - Impact of the Preparation Method of Red Cell Concentrates on Transfusion Indices in Thalassemic Patients Phase 4
Not yet recruiting NCT05777733 - NAC Effect on Iron Overload and Blood Transfusion in β-thalassemia Major Phase 1
Completed NCT01241357 - High-Tc Susceptometer to Monitor Transfusional Iron Overload Phase 2
Completed NCT00749515 - Pilot Study for Patients With Poor Response to Deferasirox Phase 4
Completed NCT04260516 - The Effect of N-acetylcysteine on Oxidative Stress Status and Iron Overload in Thalassemia Major Phase 1
Recruiting NCT02307786 - Long Term Outcomes in β Thalassemia Major N/A
Not yet recruiting NCT01323608 - The Effect of Vitamin D Supplementation on Calcium Excretion in Thalassemia: a Dose Response Study Phase 4
Completed NCT00005893 - Study of Allogeneic Bone Marrow Transplantation Using Matched, Related Donors in Patients With Nonmalignant Hematologic Disorders N/A
Recruiting NCT06137079 - "Iron Overload and Endocrinological Diseases"